Both in Pharmaceuticals
Pyxis Oncology vs Cue Biopharma
Over the past year PYXS returned −52.5% and CUE returned −3.0%; their daily moves had a correlation of -0.03.
PYXS −52.5% CUE −3.0%Growth of $1, one year, split-adjusted
| Metric | PYXS | CUE |
|---|---|---|
| Price | $1.81 | $20.87 |
| Market cap | $151.0M | $151.6M |
| Today | −4.23% | −2.70% |
| 1 month | −17.4% | −17.3% |
| 6 months | +5.2% | −31.4% |
| Year to date | +57.4% | +127.8% |
| 1 year | −45.3% | +0.8% |
| Revenue growth (YoY) | −100.0% | +166.7% |
| Gross margin | — | 100.0% |
| Net margin | — | −1943.2% |
| P/E (TTM) | — | — |
| Price / sales | 13.7× | 4.0× |
| Net cash | $33.0M | $16.4M |
| Dividend yield | — | — |
| Volatility (60d) | 112.1% | 137.1% |
| Short % of float | 7.9% | 12.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).